Advertisement

Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis

  • Guilherme Gomes Teixeira
  • Naiara Lourenço Mari
  • Jaqueline Costa Castardo de Paula
  • Tamires Flauzino
  • Marcell Alysson Batisti Lozovoy
  • Ligia Márcia Mário Martin
  • Edna Maria Vissoci Reiche
  • Michael Maes
  • Isaias Dichi
  • Andréa Name Colado SimãoEmail author
Original Article

Abstract

The objective of this study is to delineate the cellular adhesion molecule (CAM) profile and plasminogen activator inhibitor type 1 (PAI-1), and their association with metabolic syndrome (MetS) and carbohydrate metabolism biomarkers in psoriasis patients with mild and moderate severity. Sixty-seven patients with psoriasis as well as 102 healthy subjects were recruited. Insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), but not glucose, were significantly higher in psoriasis than in controls. Psoriasis was characterized by increased plasma levels of platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin, and PAI-1 as compared with controls. Psoriasis diagnosis could explain 59.0% of CAM and PAI-1 variance, with a particularly strong impact on E-selectin (45.6%), VCAM-1 (32.7%), and PAI-1 (24.8%). Subjects with MetS showed significantly higher E-selectin and PAI-1 than those without MetS. Using VCAM-1, E-selectin, PAI-1 (all positively), and P-selectin (inversely) in a binary regression equation, it was found that 87.6% of all patients were correctly classified with a sensitivity of 92.5% and a specificity of 84.3%. CAM and PAI-1 were correlated with carbohydrate metabolism biomarkers (glucose, insulin, and HOMA-IR). In conclusion, CAM levels are associated with psoriasis diagnosis and MetS may influence E-selectin and PAI-1 concentrations. More studies are needed to verify the causality among these factors, as well as their relation to the different degrees of disease severity.

Keywords

Psoriasis Cellular adhesion molecules Metabolic syndrome Plasminogen activator inhibitor type 1 Carbohydrate metabolism 

Notes

Acknowledgements

This study was supported by the National Council of Brazilian Research-CNPq and by Araucária Foundation from the state of Paraná. We thank the University Hospital of State University of Londrina for technical and administrative supports.

Funding

This research did not receive any funding.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its latter amendments or comparable ethical standards.

Informed consent

All the participants included in this study provided written informed consent.

References

  1. 1.
    Davidovici BB, Sattar N, Prinz JC, Jörg PC, Puig L, Emery P, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785–96.CrossRefGoogle Scholar
  2. 2.
    Bodemer AA. Psoriasis. Integr Med. 2018; 726.e2–38.e2.Google Scholar
  3. 3.
    Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4:a015354.CrossRefGoogle Scholar
  4. 4.
    Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8.CrossRefGoogle Scholar
  5. 5.
    Bautista-Herrera LA, De la Cruz-Mosso U, Morales-Zambrano R, Villanueva-Quintero GD, Hernández-Bello J, Ramírez-Dueñas MG, et al. Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables. Clin Exp Med. 2018;18:229–35.CrossRefGoogle Scholar
  6. 6.
    Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M, et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res. 2019;68:557–67.CrossRefGoogle Scholar
  7. 7.
    Čabrijan L, Lipozenčić J. Adhesion molecules in keratinocytes. Clin Dermatol. 2011;29:427–31.CrossRefGoogle Scholar
  8. 8.
    Sanchez APG. Imunopatogênese da psoríase. An Bras Dermatol. 2010;85:747–9.CrossRefGoogle Scholar
  9. 9.
    Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–14.CrossRefGoogle Scholar
  10. 10.
    Griffiths CE, Boffa MJ, Gallatin WM, Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in Psoriasis. Acta Derm Venereol. 1996;76:2–5.PubMedGoogle Scholar
  11. 11.
    Torres-Alvarez B, Castanedo-Cazares JP, Fuentes-Ahumada C, Moncada B. The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis. J Eur Acad Dermatol Venereol. 2007;21:334–9.  https://doi.org/10.1111/j.1468-3083.2006.01916.x.CrossRefPubMedGoogle Scholar
  12. 12.
    Bressan AL, Picciani BLS, Azulay-Abulafia L, Fausto-Silva AK, Almeida PN, Cunha KSG, et al. Evaluation of ICAM-1 expression and vascular changes in the skin of patients with plaque, pustular, and erythrodermic psoriasis. Int J Dermatol. 2018;57:209–16.  https://doi.org/10.1111/ijd.13883.CrossRefPubMedGoogle Scholar
  13. 13.
    Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 2002;51:563–7.CrossRefGoogle Scholar
  14. 14.
    Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS ONE. 2017;12:e0181039.  https://doi.org/10.1371/journal.pone.0181039.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(657–666):e8.Google Scholar
  16. 16.
    Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36:21–8.CrossRefGoogle Scholar
  17. 17.
    Chen NG, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab. 1999;84:3485–9.  https://doi.org/10.1210/jcem.84.10.6065.CrossRefPubMedGoogle Scholar
  18. 18.
    Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011;63:1–9.CrossRefGoogle Scholar
  19. 19.
    Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol. 2013;44:194–204.  https://doi.org/10.1007/s12016-012-8308-0.CrossRefPubMedGoogle Scholar
  20. 20.
    da Rosa Franchi Santos LF, Stadtlober NP, Costa Dall’Aqua LG, Scavuzzi BM, Guimarães PM, Flauzino T, et al. Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels. Lupus. 2018;27:380–8.  https://doi.org/10.1177/0961203317723716.CrossRefPubMedGoogle Scholar
  21. 21.
    de Sá MC, Simão ANC, de Medeiros FA, Iriyoda TMV, Costa NT, Alfieri DF, et al. Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome. Clin Exp Med. 2018;18:495–504.  https://doi.org/10.1007/s10238-018-0516-3.CrossRefPubMedGoogle Scholar
  22. 22.
    Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.CrossRefGoogle Scholar
  23. 23.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.  https://doi.org/10.1001/jama.2013.284427.CrossRefPubMedGoogle Scholar
  24. 24.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.  https://doi.org/10.1161/CIRCULATIONAHA.105.169404.CrossRefGoogle Scholar
  25. 25.
    Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.  https://doi.org/10.1161/01.CIR.101.9.975.CrossRefPubMedGoogle Scholar
  26. 26.
    Dowlatshahi EA, van der Voort EAM, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266–82.  https://doi.org/10.1111/bjd.12355.CrossRefPubMedGoogle Scholar
  27. 27.
    Vanizor Kural B, Örem A, Çimşit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003;332:23–30.CrossRefGoogle Scholar
  28. 28.
    Sigurdardottir G, Ekman A-K, Ståhle M, Bivik C, Enerbäck C. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis. J Am Acad Dermatol. 2014;70:1067–75.CrossRefGoogle Scholar
  29. 29.
    Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol. 2017;44:363–9.  https://doi.org/10.1111/1346-8138.13661.CrossRefPubMedGoogle Scholar
  30. 30.
    Death AK, McGrath KCY, Sader MA, Nakhla S, Jessup W, Handelsman DJ, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology. 2004;145:1889–97.CrossRefGoogle Scholar
  31. 31.
    Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–32.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019;180:94–9.  https://doi.org/10.1111/bjd.16885.CrossRefPubMedGoogle Scholar
  33. 33.
    Schlüter K, Diehl S, Lang V, Kaufmann R, Boehncke W-H, Bürger C. Insulin resistance may contribute to upregulation of adhesion molecules on endothelial cells in psoriatic plaques. Acta Derm Venereol. 2016;96:162–8.  https://doi.org/10.2340/00015555-2227.CrossRefPubMedGoogle Scholar
  34. 34.
    Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5(Suppl 1):132–42.  https://doi.org/10.1111/j.1538-7836.2007.02464.x.CrossRefPubMedGoogle Scholar
  35. 35.
    Garshick MS, Barrett TJ, Wechter T, Azarchi S, Scher JU, Neimann A, et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol. 2019;39:787–98.  https://doi.org/10.1161/ATVBAHA.118.312246.CrossRefPubMedGoogle Scholar
  36. 36.
    Yan K, Han L, Deng H, Fang X, Zhang Z, Huang G, et al. The distinct role and regulatory mechanism of IL-17 and IFN-γ in the initiation and development of plaque vs guttate psoriasis. J Dermatol Sci. 2018;92:106–13.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Guilherme Gomes Teixeira
    • 1
  • Naiara Lourenço Mari
    • 1
  • Jaqueline Costa Castardo de Paula
    • 1
  • Tamires Flauzino
    • 1
  • Marcell Alysson Batisti Lozovoy
    • 1
    • 2
  • Ligia Márcia Mário Martin
    • 3
    • 4
  • Edna Maria Vissoci Reiche
    • 1
    • 2
  • Michael Maes
    • 5
    • 6
  • Isaias Dichi
    • 4
  • Andréa Name Colado Simão
    • 1
    • 2
    Email author
  1. 1.Research Laboratory in Applied ImmunologyUniversity of LondrinaLondrinaBrazil
  2. 2.Department of Pathology, Clinical Analysis and ToxicologyUniversity of LondrinaLondrinaBrazil
  3. 3.Department of DermatologyUniversity of LondrinaLondrinaBrazil
  4. 4.Department of Internal MedicineUniversity of LondrinaLondrinaBrazil
  5. 5.IMPACT Strategic Research Centre, School of MedicineDeakin UniversityGeelongAustralia
  6. 6.Department of Psychiatry, Faculty of MedicineChulalongkorn UniversityBangkokThailand

Personalised recommendations